After the European Medicines Agency (EMA) approves a new cancer drug, reimbursement decisions by each country’s health authorities can take up to one year, with wide variations between countries. according to a study just presented [more]
How do you decide which new cancer drugs to approve, when statistical certainty takes too long to wait for and essential evidence on quality of life is hard to measure? The head of the cancer [more]
Little by little, patient advocates are winning their battle to be involved in decisions that affect them. They are now focusing on how to use their new-found voice to deliver real change for the people [more]
Faced with escalating drug prices and rising patient expectations, Europe’s governments are anxious to ensure value for money from their overstretched health budgets. But how can one measure the value of a few extra precious [more]